How NICE may be outflanked.
作者信息
Ferner R E, McDowell Sarah E
机构信息
West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham B18 7QH.
出版信息
BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268.
Abstract
摘要
相似文献
1
How NICE may be outflanked.英国国家卫生与临床优化研究所（NICE）可能如何被智取。
BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268.
2
NICE work: nice try.干得漂亮：想得倒美。
BMJ. 2006 Jun 10;332(7554):1394. doi: 10.1136/bmj.332.7554.1394.
3
4
Cost-effectiveness considerations at NICE.英国国家卫生与临床优化研究所的成本效益考量
Lancet. 2008 Oct 11;372(9646):1302. doi: 10.1016/S0140-6736(08)61550-0.
5
Should NICE's threshold range for cost per QALY be raised? No.国家卫生与临床优化研究所（NICE）每质量调整生命年（QALY）的成本阈值范围应该提高吗？不应该。
BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.
6
Review of NICE's recommendations, 1999-2005.英国国家卫生与临床优化研究所（NICE）1999 - 2005年建议回顾。
BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.
7
Should NICE's threshold range for cost per QALY be raised? Yes.国家卫生与临床优化研究所（NICE）每质量调整生命年（QALY）的成本阈值范围应该提高吗？应该。
BMJ. 2009 Jan 26;338:b181. doi: 10.1136/bmj.b181.
8
On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.英国的“国民健康与临床优化研究所”（NICE）：英格兰和威尔士国民医疗服务体系（NHS）技术评估指南
Health Econ. 2002 Apr;11(3):185-91. doi: 10.1002/hec.706.
9
Challenges in Using MCDA for Reimbursement Decisions on New Medicines?在使用多标准决策分析（MCDA）进行新药报销决策时面临的挑战？
Value Health. 2016 Mar-Apr;19(2):123-4. doi: 10.1016/j.jval.2016.02.001. Epub 2016 Mar 10.
10
From rationing to rational: the evolving status of NICE.从定量配给到合理配置：英国国家卫生与临床优化研究所的发展现状
J R Soc Med. 2008 Sep;101(9):436-42. doi: 10.1258/jrsm.2008.080167.
引用本文的文献
1
A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.政策影响的隐秘网络：制药业与英国各党派议会团体的互动。
PLoS One. 2021 Jun 24;16(6):e0252551. doi: 10.1371/journal.pone.0252551. eCollection 2021.
2
Exposing drug industry funding of UK patient organisations.揭露英国患者组织的药品行业资助情况。
BMJ. 2019 May 22;365:l1806. doi: 10.1136/bmj.l1806.
3
If You're a Rawlsian, How Come You're So Close to Utilitarianism and Intuitionism? A Critique of Daniels's Accountability for Reasonableness.如果你是罗尔斯主义者，为何你如此接近功利主义和直觉主义？对丹尼尔斯“合理的可问责性”观点的批判
Health Care Anal. 2018 Mar;26(1):1-16. doi: 10.1007/s10728-017-0343-9.
4
Accounting for failure: risk-based regulation and the problems of ensuring healthcare quality in the NHS.对失败的考量：基于风险的监管与英国国家医疗服务体系中确保医疗质量的问题。
Health Risk Soc. 2016 May 18;18(3-4):205-224. doi: 10.1080/13698575.2016.1192585. Epub 2016 Jun 27.
5
Academics and competing interests in H1N1 influenza media reporting.甲型 H1N1 流感媒体报道中的学术界和利益冲突。
J Epidemiol Community Health. 2014 Mar;68(3):197-203. doi: 10.1136/jech-2013-203128. Epub 2013 Nov 11.
6
7
When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.何时他汀类药物在心血管预防方面具有成本效益？他汀类药物经济学评价中的赞助偏见和结论的系统评价。
PLoS One. 2013 Jul 8;8(7):e69462. doi: 10.1371/journal.pone.0069462. Print 2013.
8
Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test.行业参与和成本效益分析的基本假设：巴氏涂片检查的诊断准确性。
CMAJ. 2011 Apr 5;183(6):E337-43. doi: 10.1503/cmaj.101506. Epub 2011 Mar 14.
9
Pedagogical promise and problems: teaching public health law.教学前景与问题：公共卫生法教学
Public Health. 2009 Mar;123(3):222-31. doi: 10.1016/j.puhe.2008.12.022. Epub 2009 Feb 24.
10
The impact of cancer research: how publications influence UK cancer clinical guidelines.癌症研究的影响：出版物如何影响英国癌症临床指南。
Br J Cancer. 2008 Jun 17;98(12):1944-50. doi: 10.1038/sj.bjc.6604405. Epub 2008 Jun 3.
本文引用的文献
1
Review of NICE's recommendations, 1999-2005.英国国家卫生与临床优化研究所（NICE）1999 - 2005年建议回顾。
BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.
2
Seven years of feast, seven years of famine: boom to bust in the NHS?七年盛宴，七年饥荒：英国国家医疗服务体系会由盛转衰吗？
BMJ. 2006 Apr 15;332(7546):906-8. doi: 10.1136/bmj.332.7546.906.
3
What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews.有哪些证据表明英国国家卫生与临床优化研究所（NICE）的指南已得到实施？一项使用时间序列分析、患者病历审核和访谈的全国性评估结果。
BMJ. 2004 Oct 30;329(7473):999. doi: 10.1136/bmj.329.7473.999.
4
Increasing use of a new health technology during the wait for NICE guidance: findings from the third national tracker survey of photodynamic therapy.在等待英国国家卫生与临床优化研究所（NICE）指南期间新型健康技术使用的增加：第三次光动力疗法全国追踪调查的结果
J Public Health (Oxf). 2004 Mar;26(1):52-5. doi: 10.1093/pubmed/fdh112.
5
6
Relationships between the pharmaceutical industry and patients' organisations.制药行业与患者组织之间的关系。
BMJ. 2003 May 31;326(7400):1208-10. doi: 10.1136/bmj.326.7400.1208.
7
The price of innovation: new estimates of drug development costs.创新的代价：药物研发成本的新估计
J Health Econ. 2003 Mar;22(2):151-85. doi: 10.1016/S0167-6296(02)00126-1.
8
Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.利益冲突与作者结论之间的关联：对发表于《英国医学杂志》的随机临床试验的流行病学研究
BMJ. 2002 Aug 3;325(7358):249. doi: 10.1136/bmj.325.7358.249.
9
Selling sickness: the pharmaceutical industry and disease mongering.贩卖疾病：制药行业与疾病兜售
BMJ. 2002 Apr 13;324(7342):886-91. doi: 10.1136/bmj.324.7342.886.
10
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.肿瘤学中使用的新药经济分析中的利益冲突评估。
JAMA. 1999 Oct 20;282(15):1453-7. doi: 10.1001/jama.282.15.1453.
Zotero 插件